M&A deals, company strategies, pipeline updates and more
Follow our coverage of the 2019 J.P. Morgan Healthcare Conference in San Francisco
Here is some other vaccine news of note for the week.
Takeda's dengue vaccine induced sustained antibody responses in children, topline phase 2 data showed.
Aviragen and Vaxart merged into one company aimed at developing oral vaccines against flu, norovirus and RSV.
Here is some other vaccine news of note for this week.
China's FDA approved a domestically developed Ebola vaccine based on a different virus type from GSK's and Merck's shots.
No currently available vaccines against typhoid are meant for children younger than 2, but a new WHO endorsement could change that.
Young biotech Codagenix just secured $3 million in funding to advance its live-attenuated RSV vaccine candidate.
A large-scale phase 3 study shows that Merck's Gardasil 9 vaccine protects against HPV-related cancers for at least six years.
Researchers in England are kicking off the world's first large human trial of a "universal" influenza shot.
Serum Institute of India has new results from a phase 3 trial of its rotavirus vaccine as it preps to deliver millions of doses.